REO 007 was an open-label, dose-escalation Phase I monotherapy study for patients with recurrent malignant gliomas who were refractory to standard therapy. Each patient received a single dose of REOLYSIN®, infused into the tumour mass and surrounding area. Fifteen patients were enrolled in the study. The primary objectives were to determine the maximum tolerated dose, dose-limiting toxicity and safety.
The Company announced results from the study in April 2010. The treatment was shown to be safe and well tolerated, with no maximum tolerated dose reached.